HCW Biologics (HCWB) vs Onconetix (ONCO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
HCW Biologics is the larger company by market cap ($3.6 million vs $3.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | ONCO |
|---|---|---|
| Share price | $1.60 | $0.62 |
| Market cap | $3.58M | $3.25M |
| 1-day change | +4.58% | -5.24% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-21.01 | $310.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $200.00 |
| 52-week low | $1.50 | $0.58 |
| Distance from 52-week high | -94.14% | -99.69% |
| Analyst consensus | buy | — |
| Avg. price target upside | +2900.00% | — |
| Average volume | 381.72K | 2.94M |
| Shares outstanding | 2.24M | 5.24M |
| Employees | 35 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Onconetix
ONCO stock →Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
HCWB vs ONCO FAQ
Which is bigger, HCW Biologics or Onconetix?
HCW Biologics (HCWB) is larger, with a market capitalization of $3.58M compared with $3.25M for Onconetix (ONCO).
Are HCW Biologics and Onconetix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.